INCY Q3 Earnings Miss Estimates, Revenues Beat on Higher Product Sales

Incyte Corporation (INCY) reported third-quarter 2024 adjusted earnings of $1.07 per share, which missed the Zacks Consensus Estimate of$1.12. The company recorded earnings of $1.10 per share in the year-ago quarter. Total revenues in the reported quarter were$1.14 billion, which grew 23.8% year over year, driven by the sustained performance of its lead drug, Jakafi (ruxolitinib), and increased sales of Opzelura (ruxolitinib) cream on strong launch and demand. The top line beat the Zacks Consensus Estimat ...